Ingen Technologies Reports Top and Bottom Line Improvements in 2010

Top Quote Revenues Up 1,139%, Debt Reduced by 60%, Cash Steady at $400,000 in the First Quarter of 2010 End Quote
  • (1888PressRelease) July 23, 2010 - Ingen Technologies, Inc. (OTCMarkets: IGNT), an emerging medical device manufacturer developing innovative solutions for the respiratory market, with a new patented and proprietary medical product line targeting the $8 billion respiratory market, reported revenues that increased 1,139%, from $10,401 during the first quarter of 2009 to $128,917 during the first quarter of 2010. Shareholders from companies such as Paradigm Medical Industries Inc. (PDMI) and Cardiovascular Systems Inc. (CSII) are taking notice of this uptrend.

    The company also reduced its debt by 60% from about $5 million in 2009 to about $1.8 million in 2010, and preserved its cash position at around $400,000. While the company De-Registered from the SEC (Filed Dec 4, 2008) to continue funding its product development, it plans to file its annual report next week and finalize its audited restatements later this month, continuing its efforts to return as a fully reporting company by the end of this year.

    "Ingen has commenced an aggressive sales push during the first part of 2010 that is just starting to pay operational costs, thanks partly to market branding, acceptance and awareness of the Smart Nasal Cannula with its Oxyview technology and to its recent ISO certification and government contract program," said Ingen Technologies CEO Scott Sand. "At the same time, we remain focused on improving our balance sheet and becoming a current reporting company in order to attract institutional investors and unlock shareholder value."

    Investors can review our current fact sheet at the following link:

    Company Websites:

  • FB Icon Twitter Icon In-Icon
Contact Information